[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634873":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":28,"collaborators":10,"id":32,"slug":10,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":51,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1: MASLD participants with elevated liver fat burden",null,"Participants with higher UDFF values.",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2: MASLD participants with lower liver fat burden","Participants with lower UDFF values.",[16],{"facility":17,"status":10,"city":18,"state":19,"zip":10,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":10},"The First Affiliated Hospital, Sun Yat-sen University","Guangzhou","Guangdong","China","CN",{"type":23,"coordinates":24},"Point",[25,26],113.25,23.11667,{"lat":26,"lon":25},{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Minjie Wan","Dr","100634873",false,"NCT07545343","Integrated Ultrasound-Derived Fat Fraction and 2D\u002F4D HeartAI for Cardiovascular Risk Management in Patients With MASLD","Integration of Ultrasound-Derived Fat Fraction With 2D and 4D HeartAI for Cardiovascular Risk Management in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Observational Cohort Study","MUCHAI","Inclusion Criteria:\n\n* Adults aged 18 to 75 years\n* Diagnosis of MASLD based on imaging or biopsy\n* Presence of at least one cardiometabolic risk factor, such as BMI ≥25 kg\u002Fm², type 2 diabetes mellitus, or dyslipidemia\n* No contraindication to ultrasound imaging\n\nExclusion Criteria:\n\n* Significant alcohol consumption: \\>20 g\u002Fday for women or \\>30 g\u002Fday for men Secondary causes of hepatic steatosis, such as viral hepatitis or autoimmune liver disease\n* Known advanced heart failure (New York Heart Association class III-IV)\n* Recent cardiovascular event within 6 months\n* Pregnancy\n* Inability to complete follow-up","ALL","18 Years","75 Years",{"count":43,"type":44},700,"ESTIMATED","OBSERVATIONAL","This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo baseline assessment and repeat evaluations at 6, 12, and 36 months. The study will assess the diagnostic performance of integrated UDFF-HeartAI analysis for detecting subclinical cardiac abnormalities and identify predictors of cardiovascular risk progression and major adverse cardiovascular events in patients with MASLD.",[48,49,50],"MASLD","Cardiovascular (CV) Risk","Subclinical Cardiovascular Impairments",[52,53,54,55],"Ultrasound-Derived Fat Fraction","Echocardiography","Cardiovascular Events","Major Adverse Cardiovascular Events","NOT_YET_RECRUITING","2026-04-16",{"date":59,"type":60},"2026-04-22","ACTUAL",{"date":62,"type":44},"2026-06-01",{"date":64,"type":44},"2030-05-31",{"name":5,"class":6},1]